Remove 2003 Remove Leads Remove Prescription
article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

Dry eye syndrome (DES) is an indication whose mainstay treatment has been dominated by Allergan’s Restasis (cyclosporine ophthalmic emulsion 0.05%) ever since its launch in 2003 in the US. Current treatment options for DES are dominated by a mix of prescription and over-the-counter (OTC) products.

article thumbnail

Direct to Patient Healthcare

Healthcare Success

Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. I'm like that new prescription. It was scary. But let's get back to. So, I love this model like I said.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Cosmetic Surgery Companies in US

Medico Reach

Sientra delivers leading transformative treatments and technologies concentrated on advancing the art of plastic surgery and making a difference in users lives. Location: California Website: sientra.com Established year: 2003 Revenue: $90.3 Sientra is a medical aesthetics establishment with body contouring creations and implants.

Medical 52
article thumbnail

How the U.S. election could impact the healthcare industries

Clarivate

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries. Pillo, Senior Healthcare Research and Data Analyst; and Paula Wade, Lead Healthcare Research and Data Analyst.